Why does Lyrica® (generic name pregabalin) help some FM patients and not others?
The Department of Anesthesiology at the University of Utah , Salt Lake City, announced July 10 that it is seeking participants for a study to investigate Lyrica’s “effects on blood biomarkers” in patients with fibromyalgia or FM & chronic fatigue syndrome (ME/CFS).
Lyrica (pregabalin) is a prescription drug marketed by Pfizer that gained FDA approval in 2007* for treatment of fibromyalgia.
Subscribe to the World's Most Popular Newsletter (it's free!)
According to the July 10 blood biomarkers study announcement:
• Researchers hope to learn more about why Lyrica is effective for some patients and not for others.
• Volunteers with fibromyalgia (FMS) or chronic fatigue syndrome and FMS who are not currently using Lyrica are needed to participate in this IRB-approved trial.
• Eligible volunteers will receive Lyrica for five weeks and a placebo for five weeks, and will be compensated for their time.
• For more information, contact Andrea White (firstname.lastname@example.org )
* As Pfizer’s Lyrica patents begin expiring, in October 2013, the $3.4 billion annual Lyrica market will be opening to ‘generic’ (generally lower price) versions of the drug, and as of July 5, the FDA approved marketing of a generic pregabalin product  by Lupin Pharmaceuticals.